It was proposed recently that AD progression time may be divided into three phases: damaging phase, where amyloid beta (Aβ) and hyperphosphorylated microtubule-associated protein tau (MAP tau, MAPT) accumulate; synaptic and metabolic alteration phase; and final phase when clinical symptoms may be detected [1, 2]. This evidence concerns the gene MAPT and Alzheimer disease.